<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03204071</url>
  </required_header>
  <id_info>
    <org_study_id>GDCRI/ACM/PG/PhD/2/2015-2016IG</org_study_id>
    <nct_id>NCT03204071</nct_id>
  </id_info>
  <brief_title>Locally Delivered Metformin and Aloe Vera for Treatment of Intrabody Defects in Chronic Periodontitis</brief_title>
  <official_title>COMPARATIVE EVALUATION OF SUBGINGIVALLY DELIVERED 1% METFORMIN AND ALOE VERA GEL IN TREATMENT OF INTRABODY DEFECTS IN CHRONIC PERIODONTITIS SUBJECTS: A RANDOMIZED CONTROLLED CLINICAL TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Government Dental College and Research Institute, Bangalore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Government Dental College and Research Institute, Bangalore</source>
  <brief_summary>
    <textblock>
      Metformin (MF), a biguanide group of anti-diabetic drug has been shown to enhance osteoblasts&#xD;
      differentiation and inhibit osteoclast differentiation in vitro, thus may exhibit a favorable&#xD;
      effect on alveolar bone.&#xD;
&#xD;
      AloeVera Gel had also been used in dentistry and showed good results.The present study aims&#xD;
      to explore the efficacy of 1% MF gel and aloe vera gel as a local drug delivery system in&#xD;
      adjunct to scaling and root planing (SRP) for the treatment of subjects with chronic&#xD;
      periodontitis (CP) with intrabody defects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: To compare the efficacy of locally delivered 1% MF gel and aloe vera gel in treatment of&#xD;
      intrabony defects in chronic periodontitis subjects and compare it with placebo gel.&#xD;
&#xD;
      Methods: Ninety subjects were categorized into three treatment groups: Placebo, aloevera&#xD;
      gel(AV) and 1% Metformin (MF)after Scaling and root planning (SRP). Clinical parameters were&#xD;
      recorded at baseline, 6 and 12 months; they included plaque index (PI), modified sulcus&#xD;
      bleeding index (mSBI), pocket probing depth (PPD), and clinical attachment level (CAL).&#xD;
      Radiologic assessment of intra-bony defect (IBD) and percentage defect depth reduction (DDR%)&#xD;
      was done at baseline, 6 months and 12 months interval using computer-aided software Results:&#xD;
      Mean PPD reduction and mean CAL gain was found to greater in MF group than AV and placebo&#xD;
      group at all visits. The DDR% was greater in MF group as compared to AV and placebo group.&#xD;
&#xD;
      Conclusion: There was a greater decrease in mSBI and PPD and more CAL gain at the sites&#xD;
      treated with AV and MF as an adjunct to SRP in chronic periodontitis subjects with intrabony&#xD;
      defects as compared to placebo. The significant IBD depth reduction effect was seen in case&#xD;
      of MFgroup.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bone defect fill</measure>
    <time_frame>baseline - 6 months &amp; baseline -12 months</time_frame>
    <description>Assessed in percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in modified sulcus bleeding index</measure>
    <time_frame>baseline, 6 &amp; 12 months</time_frame>
    <description>scale 0-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plaque index</measure>
    <time_frame>baseline, 6 &amp; 12 months</time_frame>
    <description>scale 0-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pocket probing depth</measure>
    <time_frame>baseline, 6 &amp; 12 months</time_frame>
    <description>measured in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical attachment level</measure>
    <time_frame>baseline, 6 &amp; 12 months</time_frame>
    <description>measured in mm</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Chronic Periodontitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel without active ingredient to be delivered at baseline, 6 and 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aloe vera gel to be delivered at baseline, 6 and 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1% metformin gel to be delivered at baseline, 6 and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo gel</intervention_name>
    <description>Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>inactive drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aloevera</intervention_name>
    <description>Oral prophylaxis followed by placement of aloevera gel</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>AV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Oral prophylaxis followed by placement of metformin gel</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>MF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Systemically healthy patients with sites showing PPD ≥ 5 mm, CAL ≥ 4 mm and vertical bone&#xD;
        loss ≥ 3 mm on intraoral periapical radiographs, with no history of periodontal therapy in&#xD;
        the last 6 months.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects allergic to MF or AV Those on systemic MF or AV therapy Subjects with&#xD;
             aggressive periodontitis Immunocompromised subjects Use of tobacco in any form,&#xD;
             alcoholics Lactating, and pregnant females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Government Dental College and Research Institute, Bangalore</investigator_affiliation>
    <investigator_full_name>Dr. A R Pradeep</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

